Learn about the latest advances in inflammatory bowel disease (IBD) and advanced endoscopic procedures from the experts of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai. Ever since Mount Sinai physician Burrill Crohn, MD, and colleagues described the condition now known as Crohn’s disease, Mount Sinai gastroenterologists have been on the cutting edge of diagnosing and treating IBD and other gastrointestinal disorders. Bruce Sands, MD, MS is the Chief of the Division of Gastroenterology and Director of the Digestive Disease Institute. A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Our Susan and Leonard Feinstein IBD Clinical Center, led by Jean-Frederic Colombel, MD, and Marla Dubinsky, MD, is at the forefront of research into the causes of IBD and leads the field in clinical trials that have advanced patient care. Additionally, at our Center for Advanced Colonoscopy and Therapeutic Endoscopy at Sinai (CACTES), our physicians are pioneering new tools and techniques to identify, diagnose, and treat the most complex digestive disorders.
The Gastroenterology & GI Surgery Division at the Mount Sinai Hospital is ranked No. 6 in the nation by U.S. News & World Report® for 2023-24.
Learn about the latest advances in inflammatory bowel disease (IBD) and advanced endoscopic procedures from the experts of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai. Ever since Mount Sinai physician Burrill Crohn, MD, and colleagues described the condition now known as Crohn’s disease, Mount Sinai gastroenterologists have been on the cutting edge of diagnosing and treating IBD and other gastrointestinal disorders. Bruce Sands, MD, MS is the Chief of the Division of Gastroenterology and Director of the Digestive Disease Institute. A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Our Susan and Leonard Feinstein IBD Clinical Center, led by Jean-Frederic Colombel, MD, and Marla Dubinsky, MD, is at the forefront of research into the causes of IBD and leads the field in clinical trials that have advanced patient care. Additionally, at our Center for Advanced Colonoscopy and Therapeutic Endoscopy at Sinai (CACTES), our physicians are pioneering new tools and techniques to identify, diagnose, and treat the most complex digestive disorders.
The Gastroenterology & GI Surgery Division at the Mount Sinai Hospital is ranked No. 6 in the nation by U.S. News & World Report® for 2023-24.
The U.S. Food and Drug Administration has approved mirikizumab as a treatment for ulcerative colitis (UC) based on a pair of groundbreaking trials led by Mount Sinai’s gastroenterology team.
Newly popular obesity drugs like Ozempic® and Wegovy® are among several undergoing clinical trials at Mount Sinai for nonalcoholic steatohepatitis, or NASH.
A first-of-its-kind Mount Sinai program known as iNourish offers a full range of nutrition-focused clinical and research initiatives to support individuals with Crohn’s disease and ulcerative colitis. This platform includes a dedicated ...
A multi-target stool-based DNA test for colorectal cancer that has become commercially popular offers promise as a complement to colonoscopic evaluations for patients with ulcerative colitis (UC) and Crohn’s disease (CD). The study was ...
Mount Sinai researchers are pioneering the use of non-invasive stickers placed on the skin to give the equivalent of a skin biopsy for pediatric patients suspected of having inflammatory bowel disease. The skin cells retrieved by the tapes ...
The increasing use of biologic agents for chronic treatment of Crohn’s disease and ulcerative colitis has meant that corticosteroids are typically reserved for use during flares. The intermittent use of these efficacious therapies has ...
This year’s report illustrates not only the depth but also the breadth of the expertise to be found at the Mount Sinai Health System’s Dr. Henry D. Janowitz Division of Gastroenterology.
A recently launched Mount Sinai Health System program brings community physicians who treat inflammatory bowel disease (IBD) patients together with the Health System's renowned IBD experts in the Dr. Henry D. Janowitz Division of Gastroenterology ...
Approximately 10 percent of pancreatic ductal adenocarcinoma is due to a hereditary or genetic predisposition, including variants in the breast and ovarian cancer syndrome genes BRCA1 and BRCA2.
Two recent studies at the Icahn School of Medicine at Mount Sinai urge increased attention to training physicians about disorders of gut-brain interaction, a little-understood class of functional GI diseases.
Annual Pap tests for anal cancer don't always identify precancerous lesions, so a Mount Sinai surgeon partnered with medical device manufacturers to improve a high-resolution anoscopy device that would more effectively identify anal lesions.
Mount Sinai's Center for Gastrointestinal Physiology and Motility is the largest center of its type in New York City and one of a handful in the country offering advanced diagnostics and treatment for patients with often-complex motility disorders.
The odds of having moderate-to-severe hepatic steatosis, a component of nonalcoholic fatty liver disease, are more than three times higher among World Trade Center first responders than in a comparison group of nonresponders, a new Mount Sinai study has shown.
Marla C. Dubinsky, MD, Professor of Pediatrics, and Medicine (Gastroenterology), at the Icahn School of Medicine at Mount Sinai and Chief of the Division of Pediatric Gastroenterology at Mount Sinai Kravis Children’s Hospital, is a winner ...
In the United States, cholangiocarcinoma, or bile duct cancer, is relatively rare, although its incidence is growing for reasons experts have yet to identify. Because of its rarity, research into it has been scarce. But a Mount Sinai researcher ...
You are invited to join world-class MASLD/MASH (NAFLD/NASH) experts from the Icahn School of Medicine at Mount Sinai, Harvard Medical School, University of Chicago School of Medicine, and Arizona Liver Health as they discuss the most recent ...
Mount Sinai Health System is leading the fight against hepatitis B, having launched a universal screening and vaccination campaign across New York City in the fall of 2022, while heading up the development of a bold new set of guidelines ...
Women with liver disease who underwent standard in vitro fertilization treatment showed no statistically significant differences in the rates of conception, pregnancy loss, or live births compared to women without liver disease...
Upadacitinib, the first oral treatment for Crohn's disease, has been approved by the Food and Drug Administration. The approval came in part through a Mount Sinai-led clinical trial that showed it to be more efficacious than placebo.
In war-torn Ukraine, doctors are struggling to deliver quality care to the sick and are unable to travel for educational opportunities due to war-time restrictions. Jean-Frederic Colombel, MD and his team, determined to find ways to help ...
Mount Sinai is the first adult and pediatric inflammatory bowel disease center in the United States certified to use intestinal ultrasound for patient care and research.
Diversity, equity, and inclusion are integral aspects of the academic and clinical work performed by the Mount Sinai Health System's endoscopy team. They are also critical to providing the best possible patient care.
A clinical study of autologous stem cell transplantation for severe Crohn's disease is offering the sickest of patients a transformative therapy that is achieving remarkable early results in this group for whom nothing in the past has worked.
Mount Sinai has launched a system of digital alerts that appear on the screens of primary care physicians when a patient in their offices is a candidate for testing, vaccination, or treatment for hepatitis B.
Recent studies underscore the benefit of high-risk pancreatic surveillance programs that have helped push three-year survival rates as high as 85 percent in some cases, in large part by catching a higher proportion of malignant lesions ...
Mount Sinai researchers have found strong evidence that before the first symptoms of Crohn’s disease and ulcerative colitis occur, there’s a preclinical phase in which immune and inflammatory pathways are already altered.
A head-to-head randomized controlled trial found similar remission rates for two leading biologic therapies for Crohn's disease: ustekinumab and adalimumab.
Mount Sinai-led researchers have discovered for the first time a highly dysregulated B cell response in ulcerative colitis that opens the door to potential new biomarkers and therapeutic strategies for it as well as other types of inflammatory bowel disease.
Two new grants from Pfizer will help Mount Sinai educate primary care providers on how to identify at-risk patients and address inequities in diagnosis and care of nonalcoholic steatohepatitis.
In this report, you’ll learn about our discovery that Crohn’s disease and ulcerative colitis have a years-long preclinical phase in which immune and inflammatory pathways are measurably altered.
A study published last September in the New England Journal of Medicine appeared to question the benefits of colonoscopies. But many experts say they remain “the gold standard” to detect and prevent colon cancer.
An advanced radiotherapy technique called radiation segmentectomy may be effective against very early to early-stage hepatocellular carcinoma (HCC), a type of liver cancer that cannot be treated surgically or thermally.
The Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai is the only center in the country that is currently using ultrasound to monitor inflammation in inflammatory bowel disease patients.
A collaborative model between Gastroenterology and Rheumatology in the Department of Medicine at Mount Sinai is providing patients with IBD and arthritis a level of care few clinics in the world can offer, and researchers with a springboard ...
Mount Sinai Health System, which pioneered and continues to refine the technique of J-pouch surgery, has now created a Comprehensive Pouch Program to closely monitor patients after surgery, ensuring continuous, hands-on care designed to ...
Mount Sinai’s interventional endoscopy team continues to lead the field in innovation with the recent introduction of two novel procedures that are dramatically advancing treatment for patients with achalasia, necrotizing pancreatitis, ...
The Mount Sinai Division of Liver Diseases has built on its nationally recognized expertise in fibrosis and fibrotic pathways to create the NASH Center of Excellence, concentrating under one umbrella a rich diversity of clinical and research ...
Intestinal ultrasound to monitor ulcerative colitis and Crohn's disease has become the standard of care in Canada and many parts of Europe, but has never gained a foothold in the United States.
A research database known as SECURE-IBD provides a quick and robust source of information to clinicians around the world about the use of IBD therapies like corticosteroids and the widely prescribed tumor necrosis factor (TNF) antagonists ...
SARS-CoV-2 has a spike protein that tethers itself to angiotensin converting enzyme 2 (ACE2) to gain entry to cells, and the intestinal tract has the highest expression of ACE2 in the body—even higher than in the lungs.
Collaboration—among specialists in different disciplines, and between clinicians and bench scientists—is a hallmark of the Mount Sinai Health System and our Dr. Henry D. Janowitz Division of Gastroenterology. That approach is spotlighted ...
For the past four decades, the Jerry Waye, MD, Endoscopy Conference has featured case presentations at a weekly gathering of gastroenterology fellows and clinical staff at Mount Sinai.
We launched a database called SECURE-IBD that has already yielded the insight that TNF antagonists appear to be a low-risk IBD therapy where COVID-19 is concerned, and another study, called ICARUS, intended to explore the seroprevalence ...
Gastroenterology and Mount Sinai Heart are among the specialties recognized at The Mount Sinai Hospital in Newsweek’s “The World’s Best Specialized Hospitals 2021.”
The Icahn School of Medicine at Mount Sinai was ranked No. 3 in the world in U.S. News & World Report “Best University for Gastroenterology and Hepatology.” The Seventh Annual U.S. News & World Report “Best Global Universities” rankings ...
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program
The founders of Trellus Health, LLC, discuss their resiliency-driven approach to inflammatory bowel disease treatment utilizing digital tools, care coordination, and support
Christopher DiMaio, MD, discusses advanced therapeutic endoscopic procedures that can provide an alternative to surgery for gastrointestinal conditions.
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures.
Welcome to the inaugural Mount Sinai Health System Specialty Report for Liver Diseases. The publication of this report is the latest step Mount Sinai is taking to recognize and elevate the importance of hepatology as a separate specialty ...
Newly popular obesity drugs like Ozempic® and Wegovy® are among several undergoing clinical trials at Mount Sinai for nonalcoholic steatohepatitis, or NASH.
